Galmed PharmaceuticalsGLMD
GLMD
About: Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
Employees: 6
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
8% more funds holding
Funds holding: 12 [Q4 2024] → 13 (+1) [Q1 2025]
0.74% more ownership
Funds ownership: 2.97% [Q4 2024] → 3.7% (+0.74%) [Q1 2025]
44% less capital invested
Capital invested by funds: $143K [Q4 2024] → $80.4K (-$62.4K) [Q1 2025]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for GLMD.
Financial journalist opinion
Neutral
PRNewsWire
2 weeks ago
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH
Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways. Validated decrease in ANP (Atrial Natriuretic Peptide), a key clinical marker for heart failure, highlights expansion potential into broader cardiometabolic markets.
Neutral
PRNewsWire
3 weeks ago
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
TEL AVIV, Israel , May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments.
Neutral
PRNewsWire
1 month ago
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models
Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor growth in mice models. The cell killing effect in-vitro and in-vivo was due to increased autophagy and death receptor signaling.
Neutral
PRNewsWire
1 month ago
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation
The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.). The new formulation is expected to offer alternatives to both approved injectable semaglutide (Ozempic© and Wegovy©) and oral form (Rybelsus©), providing a non-invasive route that allows the medication to enter the bloodstream through the oral mucous membranes.
Neutral
PRNewsWire
1 month ago
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers
Galmed Pharmaceuticals (Nasdaq: GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to evaluate Aramchol's effect on overcoming drug resistance in gastrointestinal (GI) cancers. Aramchol, a first-in-class SCD1 inhibitor, will be studied in combination with standard therapies for advanced colorectal and liver cancers, aiming to reverse treatment resistance and improve outcomes in these high-mortality cancers.
Neutral
PRNewsWire
2 months ago
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor
Analysis of blood samples from patients treated with Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights into the biochemical and physiological effects of the drug. The pharmacodynamic signature associated with Aramchol treatment revealed a decrease in markers of chronic systemic inflammation, oxidative and cardiac stress, and atherosclerotic plaque pathogenesis.
Neutral
PRNewsWire
2 months ago
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor
– AM-001 Study represents a pivotal milestone in Galmed's transition to Aramchol Meglumine, an improved formulation of its lead compound in advanced clinical development – Aramchol Meglumine, a New Chemical Entity (NCE) protected by patents until 2035, is being developed both as a standalone agent and in novel drug combinations for multiple indications influenced by fatty acid metabolism – Initial findings suggest that the new Aramchol Meglumine formulation offers higher bioavailability than Aramchol free acid and that a once-daily, oral 200 mg dose is likely to be optimal for future trials, supporting improved patient compliance and potentially lowering manufacturing costs TEL AVIV, Israel , April 10, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today announced positive preliminary results from Part 1 of the Ph1 Bioavailability AM-001 Study of Aramchol Meglumine.
Neutral
PRNewsWire
2 months ago
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
TEL AVIV, Israel , April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the 'SEC').
Neutral
PRNewsWire
2 months ago
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy
TEL AVIV, Israel , March 20, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced the grant of a new patent related to its lead compound, Aramchol.
Neutral
PRNewsWire
8 months ago
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH) Data is confirmed using 3 objective measurements; NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis Continuous histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology TEL AVIV, Israel , Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
Charts implemented using Lightweight Charts™